Hydroxyurea in Children with Sickle Cell Disease

Nancy F. Olivieri, Elliott P. Vichinsky
1998 Journal of pediatric hematology/oncology  
Cardiac complications in sickle cell disease patients are widely expected. They may be related to iron deposition, anaemia or vasculitis. Hydroxyurea is a known drug that decreases haemoglobin (Hb) S levels. The objective of the study was to assess the effect of hydroxyurea on cardiac sequelae in children with sickle cell disease. Sixty-five sickle cell disease children were enrolled in the study; 37 of them were on regular follow up and hydroxurea treatment, whereas 28 were not. All patients
more » ... not. All patients underwent echocardiography and N-terminal pro-brain natriuretic peptide (NT-proBNP) assay. Plasma levels of NTproBNP were significantly lower in sickle cell patients who were on hydroxyurea treatment than in those without this therapy (p=0.03). NTproBNP levels showed significant correlations with p<0.05) and HbS levels (r=0.54, p<0.05). Significant positive correlations were detected between NTproBNP and echocardiography findings (r=0.64, p<0.01) including left ventricular mass index (r=0.78, p<0.01). In conclusion, hydroxyurea may reduce cardiac complications in children with sickle cell disease.
doi:10.1097/00043426-199801000-00004 pmid:9482409 fatcat:c5netfcrsncspdnd2uhftbe4r4